Sanofi Reports H1 Profit Down Over 34%, Missing Market Expectations Despite Strong Dupixent Sales

Gelonghui July 25 | Sanofi announced its Q2 and H1 performance. The net sales in H1 were €21.21 billion, increasing by 8.4% year-on-year at constant exchange rates, while analysts expected €20.82 billion; earnings per share were €1.80, decreasing by 34.3% year-on-year, while analysts expected €3.39.

Second-Quarter Sales Reach €10.745 Billion, Up 10.2% Year-over-Year at Constant Exchange Rates, Beating Analysts' Expectations of €10.42 Billion; Earnings Per Share Decline 22.6% Year-over-Year at Constant Exchange Rates to €0.89. Dupixent Sales Grow 29.2% Year-over-Year to €3.303 Billion, Exceeding the Consensus Analyst Estimate of €3.18 Billion. Dupixent is Approved for Treating Conditions Such as Asthma and Eczema. The Company Maintains Its Full-Year Sales Target for Dupixent at Approximately €13 Billion.

Benefiting from pipeline-driven transformation and accelerated delivery, the business earnings per share in 2024 will remain stable, revised upwards from the previously expected low single-digit percentage decline. Based on the average exchange rate in July, the currency impact on 2024 business earnings per share is estimated to be between -5.5% and -6.5%.